Close

SARS-CoV Virus Like Particles (VLPs)

Virus-like particles (VLPs) mimic the structure of natural virus particles without viral genomes, evocative of "empty shells". VLPs can be a highly efficient vaccine platform due to the enhanced immunogenicity. They also play the role of versatile nano-scaffolds through surface display and inside encapsulation of diverse cargos for targeted delivery, imaging, catalysis, or other applications. Creative Biolabs is an undisputed world-leading service provider of VLP technology. With rich experience and well-established platforms, we can offer leading-edge VLPs production service based on our advanced mammalian cells system and insect system, also labeled with Green Fluorescent Protein (GFP), to deliver diverse research goals.

A schematic representation of assembly VLPs derived from enveloped or nonenveloped viruses.Figure.1 A schematic representation of assembly VLPs derived from enveloped or nonenveloped viruses. (Yan, 2015)

Severe acute respiratory syndrome (SARS) was caused by a previously unrecognized animal coronavirus that exploited opportunities provided by 'wet markets' in southern China to adapt to become a virus readily transmissible between humans. In November 2002, a new 'plague' was emerging in Guangdong Province, China. On 21 February 2003 a physician from Guangdong spent a single day in hotel 'M' in Hong Kong, during which time he transmitted an infection to 16 other guests. These, in turn, seeded outbreaks of the 3 disease in Hong Kong, Toronto, Singapore and Vietnam. Within weeks, SARS had spread to affect more than 8,000 people in 25 countries across 5 continents.

The global spread of SARS.Figure.2 The global spread of SARS. (Peiris, 2004)

Previous SARS vaccine developments fall into several categories: inactivated SARS based vaccines, DNA or other recombinant viruses expressing the S spike glycoprotein subunit vaccines containing S receptor binding domain or soluble ectodomain and VLPs based vaccines. Of these, SARS VLP vaccine candidates have shown considerable promise. Recombinant VLP vaccine development has drawn increasing attention because it has the potential to be safer than inactivated or attenuated viral vaccines and to be more immunogenic than subunit or DNA vaccines.

The structural proteins of SARS, including envelope glycoproteins spike (S), envelope (E), membrane (M) and nucleocapsid (N). Based on previous researches, Creative Biolabs has successfully produced VLPs composed of S, M, and E or S, M, N, E in mammalian cells and/or insect cell expression system (baculovirus).

Schematic diagram of the SARS coronavirus structure.Figure.3 Schematic diagram of the SARS coronavirus structure. (Peiris, 2004)

With many years of experience in producing VLPs, Creative Biolabs offers end-to-end VLP production services using state-of-the-art virology techniques. The process details are always guided by the requirements of our customers. The general workflow includes:

Production, purification and characterization of VLPs.Figure.4 Production, purification and characterization of VLPs.

Creative Biolabs has a wealth of expertise in VLPs production and offers one-stop VLPs construction services for diverse research/industrial needs. According to the structure of SARS, our scientists extend VLP production expertise to SARS and develop SARS VLP successfully. Creative Biolabs is proud to offer SARS VLP products, containing S/M/E or S/M/E/N to advance SARS researches. Moreover, we provide VLP products labeled with GFP if clients want to put the dye marker for VLPs. Our professional experts are well-adept and pleased in tailoring the most reliable and cost-effective strategies for our customers to facilitate their significant research. Our excellent expert staff provides a variety of flexible and reliable solutions for our customers to facilitate their significant research. If you are interested in our services above, please feel free to contact us for more details.

References

  1. Yan, D.; et al. (2015). The application of virus-like particles as vaccines and biological vehicles. Applied microbiology and biotechnology. 2015, 99(24): 10415-10432.
  2. Peiris, J.; et al. Severe acute respiratory syndrome. Nat Med. 2004, 10:88-S97.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us